New Company Formed Through Licensing Of Cardiac-Hypertrophy Technology From Texas Institutions

November 18, 1998

DALLAS - November 18, 1998 - ManTex Biotech Inc., a company based on discoveries concerning enlargement of the heart by researchers at UT Southwestern Medical Center at Dallas and the University of North Texas Health Science Center, Fort Worth, today announced joint licensing of the technologies with the two medical institutions.

"We have made exciting progress toward understanding cardiac hypertrophy and heart failure," said Dr. Eric Olson, chairman of molecular biology and oncology at UT Southwestern and a world-renowned heart researcher. "In particular, the discovery of a calcium-signaling system that controls cardiac enlargement and the development of genetically engineered mice that mimic human heart disease, represent powerful new approaches for drug discovery. These approaches, which will be the foundation of ManTex Biotech, should lead to the rapid development of new strategies for treatment of heart disease."

Cardiac hypertrophy, which involves enlargement of the heart, is the organ's natural response to stress, including that from hypertension or heart attacks. Although initially beneficial, the enlargement eventually weakens the heart, causing it to behave like spent elastic.

"These are the first really good genetic models that target cardiac enzymes and appear to constitute the master switch in the process of cardiac hypertrophy," said Dr. Stephen Grant, director of UNT Health Science Center's cardiac and vascular molecular genetics laboratory. "We found that if this switch is left on, hearts enlarge, dramatically increasing the potential for heart failure."

The discoveries received international attention when presented in the April 17, 1998 issue of Cell. The cover article reported that two existing drugs, cyclosporine A and FK 506, could prevent hypertrophy in mice by targeting the enzyme calcineurin. At last week's American Heart Association meeting in Dallas, Olson presented additional licensed discoveries that further elucidate the molecular signals of heart enlargement. Independent sources have predicted that this technology, though in a very early stage of development, could lead to blockbuster drugs to short-circuit the disorder and prevent heart failure.

Dr. Albert Friesen, an experienced Canadian biotechnology executive, founded ManTex to develop such therapies based on the drug targets and models licensed from UT Southwestern and the University of North Texas Health Science Center. With continued involvement of the researchers, ManTex plans development of an aggressive drug-discovery program.

"This technology has already attracted considerable interest from leading biotech and pharmaceutical companies, so I believe that we will be able to build ManTex into the leading biotech company in cardiac therapy," Friesen said.

Dr. Dennis K. Stone, vice president for technology development at UT Southwestern, said formation of ManTex represents the new direction of biotechnology development in Dallas. "We are proud to participate in launching ManTex Biotech," Stone said. "The firm's founding technology will serve as a benchmark for additional biotechnology companies that will be formed as an outgrowth of research at UT Southwestern Medical Center."

UNT Health Science Center, Fort Worth, research and biotechnology dean Dr. Robert Gracy, said joint ventures such as ManTex Biotech's partnership with the two institutions will be a model for biotechnology advances in the next millennium. "The joining of these academic institutions with the biotechnology industry makes good scientific and economic sense," he said.

UT Southwestern Medical Center

Related Technology Articles from Brightsurf:

December issue SLAS Technology features 'advances in technology to address COVID-19'
The December issue of SLAS Technology is a special collection featuring the cover article, ''Advances in Technology to Address COVID-19'' by editors Edward Kai-Hua Chow, Ph.D., (National University of Singapore), Pak Kin Wong, Ph.D., (The Pennsylvania State University, PA, USA) and Xianting Ding, Ph.D., (Shanghai Jiao Tong University, Shanghai, China).

October issue SLAS Technology now available
The October issue of SLAS Technology features the cover article, 'Role of Digital Microfl-uidics in Enabling Access to Laboratory Automation and Making Biology Programmable' by Varun B.

Robot technology for everyone or only for the average person?
Robot technology is being used more and more in health rehabilitation and in working life.

Novel biomarker technology for cancer diagnostics
A new way of identifying cancer biomarkers has been developed by researchers at Lund University in Sweden.

Technology innovation for neurology
TU Graz researcher Francesco Greco has developed ultra-light tattoo electrodes that are hardly noticeable on the skin and make long-term measurements of brain activity cheaper and easier.

April's SLAS Technology is now available
April's Edition of SLAS Technology Features Cover Article, 'CURATE.AI: Optimizing Personalized Medicine with Artificial Intelligence'.

Technology in higher education: learning with it instead of from it
Technology has shifted the way that professors teach students in higher education.

Post-lithium technology
Next-generation batteries will probably see the replacement of lithium ions by more abundant and environmentally benign alkali metal or multivalent ions.

Rethinking the role of technology in the classroom
Introducing tablets and laptops to the classroom has certain educational virtues, according to Annahita Ball, an assistant professor in the University at Buffalo School of Social Work, but her research suggests that tech has its limitations as well.

The science and technology of FAST
The Five hundred-meter Aperture Spherical radio Telescope (FAST), located in a radio quiet zone, with the targets (e.g., radio pulsars and neutron stars, galactic and extragalactic 21-cm HI emission).

Read More: Technology News and Technology Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to